Newsfeeds - Spark Newswire

3 minute read

Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

Today, 10:42 PM

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.

ADMP

2 minute read

3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday

By Lisa Levin

Today, 10:42 PM

U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session.

AMPH

13 minute read

Earnings

Earnings Scheduled For November 7, 2022

By Benzinga Insights

Today, 10:42 PM

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.

AAON

1 minute read

Jefferies Assumes Amphastar Pharmaceuticals at Buy, Announces Price Target of $36

By Benzinga Newsdesk

Today, 10:42 PM

Jefferies analyst Glen Santangelo assumes Amphastar Pharmaceuticals (NASDAQ:AMPH) with a Buy rating and announces Price Target of $36.

AMPH

2 minute read

Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 10:42 PM

The U.S. Food and Drug Administration (FDA) has approved Amphastar’s (NASDAQ:AMPH) New Drug Application (ND”) for Epinephrine injection…

AMPH

1 minute read

Amphastar Pharmaceuticals Q2 EPS $0.39 Beats $0.36 Estimate, Sales $123.47M Beat $119.30M Estimate

By Bill Haddad

Today, 10:42 PM

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $0.36 by 8.33 percent. This is a 85.71 percent increase over earnings of $0.21 per share

AMPH

1 minute read

Capital One Initiates Coverage On Amphastar Pharmaceuticals with Overweight Rating, Announces Price Target of $44

By Benzinga Newsdesk

Today, 10:42 PM

Capital One analyst Tim Chiang initiates coverage on Amphastar Pharmaceuticals (NASDAQ:AMPH) with a Overweight rating and announces Price Target of $44.

AMPH